 2023 should be a year of progress on kidney disease, with multiple catalysts lined up from multiple companies. Chinook Therapeutics, Inc. has the best risk-reward based on: i valuation; ii diversity of pipeline ERA and anti-APRIL; and iii clear catalyst in Q3 2023 phase 3 ALIGN data of Atrasentan. 